Biotech company Variant Bio is developing new drugs for obesity and diabetes using genetic information from Indigenous people who donated their genes. The company is committed to sharing its revenues with the donors’ communities, a move that has sparked praise from advocates.
The partnership aims to improve treatment options for those affected by these conditions. Variant Bio’s efforts are part of a growing trend in biotechnology that seeks to harness the power of genetic data to develop innovative treatments.
This story highlights the intersection of healthcare and social responsibility, as the company prioritizes fairness and transparency in its business model. As Variant Bio moves forward with its mission, it serves as an example of how industry leaders can use their expertise to drive positive change.
Source: https://www.nytimes.com/2025/01/07/health/variant-bio-novo-nordisk-indigenous-revenue-sharing.html